Loading clinical trials...

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

NCT06854952•Terns, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Female or male aged 18 to 75 years
•2. Body mass index (BMI) of:
•1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
•OR
•2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
•3. HbA1c \< 6.5%
•4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)

Exclusion Criteria

•1. Have diabetes mellitus
•2. Have obesity induced by medication or other diagnosed endocrinologic disorders
•3. Have had or are planning surgical treatment or device-based therapy for obesity
•4. Lifetime history of suicide attempt

Locations (17)

FALCON Research Site

Birmingham, Alabama, United States

FALCON Research Site

Homewood, Alabama, United States

FALCON Research Site

Tucson, Arizona, United States

FALCON Research Site

Spring Valley, California, United States

FALCON Research Site

Port Orange, Florida, United States

FALCON Research Site

Louisville, Kentucky, United States

FALCON Research Site

Marrero, Louisiana, United States

FALCON Research Site

Boston, Massachusetts, United States

FALCON Research Site

Rochester, Minnesota, United States

FALCON Research Site

City of Saint Peters, Missouri, United States

Key Dates

Start Date

March 7, 2025

Primary Completion Date

August 19, 2025

Completion Date

September 19, 2025

Last Updated

November 6, 2025

Enrollment

167

ACTUAL participants

Conditions

Overweight or Obesity

Interventions

TERN-601

DRUG

Matching Placebo

OTHER

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400

Part A: Healthy Part B: Overweight or Obesity

View study

RECRUITINGPHASE1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

NCT07150962

Overweight or Obesity

View study

RECRUITINGPHASE3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Inclusion Criteria

Exclusion Criteria

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Weight Reduction in CLBP

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss